Publications by authors named "Siddhartha Venkata Talluri"
RAGE receptor targeted bioconjuguate lipid nanoparticles of diallyl disulfide for improved apoptotic activity in triple negative breast cancer: in vitro studies.
Artif Cells Nanomed Biotechnol
March 2018
Article Synopsis
- The study identifies RAGE as a promising target for delivering drugs specifically to triple negative breast cancer (TNBC) cells.
- Researchers developed solid lipid nanoparticles (SLN) loaded with the cytotoxic agent di-allyl-disulfide (DADS) to improve its bioavailability.
- The modified nanoparticles with RAGE antibodies showed enhanced cellular uptake and greater cytotoxic effects on TNBC cells by altering the balance of proteins that regulate cell death.
Diabetic wounds are a common complication in patients with diabetes that often lead to amputation. Although the pathophysiology of diabetic wound is multifactorial, chronic inflammation and lack of tissue regeneration leads to impair wound healing in diabetes. Application of curcumin (CUR) which is a well-known anti-inflammatory and antioxidant agent could be better strategy in diabetic wound healing.
View Article and Find Full Text PDFThe current work was carried out by the principles of quality-by-design approach to develop an optimized solid lipid nanoparticles (SLNs) formulation of diallyl disulfide (DADS) through systematic statistical study. And its antitumor activity of DADS was also evaluated on breast cancer cell lines. To understand the effect of formulation variables (critical parameters) on the responses (critical quality attributes) of SLN, a 3-factor, 3-level Box-Behnken design, was explored to predict the responses such as particle size (Y1) and % entrapment efficiency (EE) (Y2) when concentration of surfactant (X1), amount of lipid (X2), and volume of solvent (X3) were selected as independent variables.
View Article and Find Full Text PDFBackground: Diabetic foot ulcers are one of the major causes of mortality in diabetic patients. Very few drugs and therapies have regulatory approval for this indication and several agents from diverse pharmacological classes are currently in various phases of clinical trials for the management of diabetic foot ulcers.
Scope: The purpose of this review is to provide concise information of the drugs and therapies which are approved and present in clinical trials.